P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06014762 |
Recruitment Status :
Recruiting
First Posted : August 28, 2023
Last Update Posted : May 13, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Diffuse Large B Cell Lymphoma Follicular Lymphoma Mantle Cell Lymphoma Marginal Zone Lymphoma Primary Mediastinal Large B-cell Lymphoma (PMBCL) Chronic Lymphocytic Leukemia | Biological: P-CD19CD20-ALLO1 Drug: Rimiducid | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 100 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-CD19CD20-ALLO1 in Subjects With Selected Relapsed/Refractory B Cell Malignancies |
Actual Study Start Date : | April 16, 2024 |
Estimated Primary Completion Date : | March 2029 |
Estimated Study Completion Date : | March 2041 |
Arm | Intervention/treatment |
---|---|
Experimental: P-CD19CD20-ALLO1 CAR-T Cells (Arm S)
P-CD19CD20-ALLO1 following conditioning chemotherapy regimen S. Rimiducid may be administered. |
Biological: P-CD19CD20-ALLO1
Single weight-based IV administration Drug: Rimiducid Single weight-based IV administration |
Experimental: P-CD19CD20-ALLO1 CAR-T Cells (Arm LD 750)
P-CD19CD20-ALLO1 following conditioning chemotherapy regimen LD 750. Rimiducid may be administered. |
Biological: P-CD19CD20-ALLO1
Single weight-based IV administration Drug: Rimiducid Single weight-based IV administration |
Experimental: P-CD19CD20-ALLO1 CAR-T Cells (Arm LD 1000)
P-CD19CD20-ALLO1 following conditioning chemotherapy regimen LD 1000. Rimiducid may be administered. |
Biological: P-CD19CD20-ALLO1
Single weight-based IV administration Drug: Rimiducid Single weight-based IV administration |
- To assess the safety and MTD of P-CD19CD20-ALLO1 based on dose limiting toxicities (DLT) [ Time Frame: Baseline through 28 days ]Number of subjects with DLT at each dose level to define an MTD
- The safety of P-CD19CD20-ALLO1 (AEs) [ Time Frame: Baseline through 36 months ]Incidence and severity of adverse events (AEs)
- The anti-B cell malignancy effect of P-CD19CD20-ALLO1 (ORR) [ Time Frame: Baseline through 15 years ]Overall Response Rate (ORR) - Percentage of patients with complete response (CR) or partial response (PR)
- The anti-B cell malignancy effect of P-CD19CD20-ALLO1 (DOR) [ Time Frame: Baseline through 15 years ]Duration of Response - Time from complete response (CR) or partial response (PR) to progressive disease
- The anti-B cell malignancy effect of P-CD19CD20-ALLO1 (PFS) [ Time Frame: Baseline through 15 years ]Progression Free Survival (PFS) - Time from P-CD19CD20-ALLO1 treatment to progressive disease
- The anti-B cell malignancy effect of P-CD19CD20-ALLO1 (OS) [ Time Frame: Baseline through 15 years ]Overall Survival (OS) - Duration of survival from time of treatment with P-CD19CD20-ALLO1
- • The effect of cell dose and LD regimen to guide selection of specific cell dose and LD regimen for further assessment in Phase 2/3 studies [ Time Frame: Baseline through 36 months ]o Cytokine release syndrome (CRS) graded using American Society for Transplantation and Cellular Therapy (ASTCT) criteria
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Must have signed written, informed consent.
- Males or females ≥ 18 years of age.
- Must have prior biopsy proven confirmed diagnosis of DLBCL, FL, MCL, MZL, PMBCL, or CLL.
-
Diagnosis of one of the following:
- DLBCL, FL, MCL, MZL, or PMBCL by World Health Organization (WHO) 2016 (Swerdlow, 2016) criteria
- CLL that meets published diagnostic criteria (Hallek, 2018):
i. Monoclonal B cells (either kappa or lambda light chain restricted) that are clonally co-expressing ≥ 1 B cell marker (CD19, CD20, or CD23) and CD5.
ii. Prolymphocytes comprising ≤ 55% of blood lymphocytes. iii. Presence of ≥ 5 × 109 B lymphocytes/L (5000/µL) in the peripheral blood (at any point since initial diagnosis).
- CLL must be documented as CD20-positive.
-
CLL must be documented as active disease meeting ≥ 1 of the following iwCLL 2018 criteria (Hallek, 2018) for requiring treatment:
- Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia (hemoglobin < 10 g/dL) and/or thrombocytopenia (platelets < 100,000/μL)
- Massive (i.e., ≥ 6 cm below the left costal margin), progressive, or symptomatic splenomegaly.
- Massive nodes (i.e., ≥ 10 cm in the longest diameter), progressive, or symptomatic lymphadenopathy.
- Progressive lymphocytosis with an increase of > 50% over a 2 month period or a lymphocyte doubling time (LDT) of < 6 months. LDT may be obtained by linear regression extrapolation of absolute lymphocyte count (ALC) obtained at intervals of 2 weeks over an observation period of 2 to 3 months. In subjects with initial blood lymphocyte counts of < 30 × 109/L (30,000/μL), LDT should not be used as a single parameter to define indication for treatment. In addition, factors contributing to lymphocytosis or lymphadenopathy other than CLL (e.g., infections) should be excluded.
- Constitutional symptoms documented in the subject's chart with supportive objective measures, as appropriate, defined as ≥ 1 of the following disease-related symptoms or signs:
i. Unintentional weight loss ≥ 10% within the previous 6 months before Screening.
ii. Significant fatigue (inability to work or perform usual activities). iii. Fevers higher than 100.5°F or 38.0°C for ≥ 2 weeks before Screening without evidence of infection.
iv. Night sweats for > 1 month before Screening without evidence of infection.
- DLBCL, FL, MCL, MZL, or PMBCL must have measurable disease as defined by Lugano 2016 criteria (Cheson, 2016).
-
Must have relapsed/refractory disease as defined by the following:
-
DLBCL, FL, MCL, or PMBCL: received at least 2 prior lines of therapy that must include rituximab, cyclophosphamide, doxorubicin hydrochloride (i.e., hydroxydaunomycin), vincristine sulfate (i.e., oncovin), and prednisone (R-CHOP) or equivalent regimen and either autologous stem cell transplant (ASCT) or autologous CD19 targeting CAR-T therapy, or not a candidate for ASCT or autologous CD19 targeting CAR-T.
OR
- MZL: received at least 2 prior lines of therapy that must include a CD20 monoclonal antibody (mAb) and a Bruton tyrosine kinase inhibitor (BTKi) OR
- CLL: received at least 2 prior lines of therapy that must include a CD20 mAb and a BTKi
-
- Must be willing to practice birth control from the time of Screening and throughout the first year of the study after P-CD19CD20-ALLO1 administration (both males and females of childbearing potential).
- Must have a negative serum pregnancy test at Screening and a negative urine pregnancy test within 3 days prior to initiating the lymphodepletion chemotherapy regimen (females of childbearing potential).
- Must be at least 90 days since ASCT, if performed.
- Must be at least 3 months since autologous CAR-T therapy if such therapy was administered (medical monitor must approve prior CAR T therapy or other prior T cell targeted therapy).
-
Must have adequate vital organ function, defined as follows (or medical monitor approval):
-
Serum creatinine ≤ 1.5 mg/dL or estimated creatinine clearance
≥ 30 mL/min as calculated using the Cockcroft Gault formula and not dialysis-dependent.
- Adequate hematologic function, including:
i. Absolute neutrophil count (ANC) ≥ 1000/μL in the absence of growth factor support (granulocyte-colony stimulating factor [G-CSF] within 7 days or peg-G-CSF within 14 days) ii. Platelet count ≥ 50,000/μL in the absence of transfusion support (platelet transfusion within 7 days) iii. Hemoglobin ≥ 8 g/dL in the absence of transfusion support (red blood cell count or whole blood within 7 days) c. Aspartate transaminase (AST) and alanine aminotransferase (ALT) ≤ 3 × the upper limit of normal (ULN), and total bilirubin ≤ 2.0 mg/dL (unless there is a history of Gilbert's Syndrome in which case bilirubin levels ≤ 3 mg/dL).
d. Left ventricular ejection fraction (LVEF) ≥ 45%. LVEF assessment must have been performed within 4 weeks of enrollment.
-
- Must have recovered from toxicities due to prior therapies to Grade ≤ 2 according to the NCI CTCAE v5.0 criteria or to the subject's prior baseline.
- Must have an ECOG performance status of 0 to 1.
Exclusion Criteria:
- Is pregnant or lactating.
- Has inadequate venous access.
- Has active hemolytic anemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), disseminated intravascular coagulation, leukostasis, or amyloidosis.
- Has an active second malignancy (not disease-free for at least 5 years) in addition to non-Hodgkin lymphoma or CLL, excluding low-risk neoplasms such as non-metastatic basal cell or cutaneous squamous cell carcinoma.
- Has active autoimmune disease, such as psoriasis, multiple sclerosis, lupus, rheumatoid arthritis, etc. (the medical monitor will determine if a disease is active and autoimmune).
- Has a history of significant central nervous system (CNS) disease, such as stroke, epilepsy, primary CNS lymphoma, etc. (the medical monitor will determine if significant).
- Has an active systemic infection (e.g., causing fevers or requiring antimicrobial treatment).
- Has a history of hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), or human T-lymphotropic virus (HTLV) infection, or any immunodeficiency syndrome. Subjects with a history of treated hepatitis C can be enrolled if negative by hepatitis C polymerase chain reaction (PCR) on multiple occasions and with medical monitor approval.
- Is positive for human herpes virus (HHV)-6 or HHV-7 infection by polymerase chain reaction (PCR) at the Screening Visit (subjects may be included in the study if they are HHV-6 or HHV-7 IgG antibody-positive but PCR-negative).
- Has New York Heart Association (NYHA) Class III or IV heart failure, unstable angina, or a history of myocardial infarction or significant arrhythmia (e.g., atrial fibrillation, sustained [> 30 seconds] ventricular tachyarrhythmias, etc.).
- Has any psychiatric or medical disorder (e.g., cardiovascular, endocrine, renal, gastrointestinal, genitourinary, immunodeficiency or pulmonary disorder not otherwise specified) that would, in the opinion of the Investigator or medical monitor, preclude safe participation in and/or adherence to the protocol (including medical conditions or laboratory findings that indicate a significant probability of not qualifying for or being unable to undergo, LD chemotherapy and/or CAR-T cell administration).
- Has received non-mAb anti-cancer medications within 2 weeks of the time of initiating LD chemotherapy.
- Has received mAb therapy within 4 weeks of initiating LD chemotherapy.
- Has received immunosuppressive medications within 2 weeks of the time of administration of P-CD19CD20-ALLO1, and/or expected to require them while on study (the medical monitor will determine if a medication is considered immunosuppressive).
- Has received systemic corticosteroid therapy ≥ 5 mg/day of prednisone or equivalent dose of another corticosteroid within 1 week or 5 half-lives (whichever is shorter) of the administration of P-CD19CD20-ALLO1 or is expected to require it during the course of the study. (Topical and inhaled steroids are permitted. Systemic corticosteroids are contraindicated after receiving P-CD19CD20-ALLO1 cells outside of study-specific guidance).
- Has CNS metastases or CNS involvement (including leptomeningeal carcinomatosis, cranial neuropathies or mass lesions, cauda equina syndrome and spinal cord compression).
- Has a history of severe immediate hypersensitivity reaction to any of the agents used in this study.
- Has a history of having undergone allogeneic or xenogeneic transplant, or has undergone autologous transplantation within 90 days. Subjects with prior history of allogeneic stem cell transplant may be enrolled if they are not on immunosuppressive medications and with medical monitor approval.
- Has received prior allogeneic genetically modified cellular therapy or was treated with experimental allogeneic cell therapy.
- History or Grade ≥ 3 HLH/MAS or neurotoxicity with prior therapies (all symptoms of HLH/MAS, neurotoxicity, or CRS from prior therapies must be resolved at the time of enrollment).
- Has positive DAT at Screening Visit
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06014762
Contact: Angie Schinkel | 858-779-3103 | clinicaltrials@poseida.com |
United States, California | |
University of California San Diego | Not yet recruiting |
La Jolla, California, United States, 92093 | |
Loma Linda University Cancer Center | Not yet recruiting |
Loma Linda, California, United States, 92354 | |
United States, Michigan | |
Wayne State - Karmanos Cancer Institute | Recruiting |
Detroit, Michigan, United States, 48201 | |
United States, New York | |
Weill Cornell Medicine | Not yet recruiting |
New York, New York, United States, 10021 | |
United States, North Carolina | |
UNC Lineberger Comprehensive Cancer Center | Not yet recruiting |
Chapel Hill, North Carolina, United States, 27599 | |
United States, Ohio | |
University of Cincinnati | Recruiting |
Cincinnati, Ohio, United States, 45206 | |
United States, Oklahoma | |
University of Oklahoma, Health Sciences Center | Recruiting |
Oklahoma City, Oklahoma, United States, 73104 | |
United States, South Carolina | |
Prisma Health - Upstate Cancer Institute | Recruiting |
Greenville, South Carolina, United States, 29605 | |
United States, Tennessee | |
Vanderbilt University Medical Center | Not yet recruiting |
Nashville, Tennessee, United States, 37232 | |
United States, Texas | |
Baylor Scott & White Research Institute | Recruiting |
Dallas, Texas, United States, 75204 |
Study Director: | Rajesh Belani, MD | Vice President, Clinical Development |
Responsible Party: | Poseida Therapeutics, Inc. |
ClinicalTrials.gov Identifier: | NCT06014762 |
Other Study ID Numbers: |
P-CD19CD20-ALLO1-001 |
First Posted: | August 28, 2023 Key Record Dates |
Last Update Posted: | May 13, 2024 |
Last Verified: | May 2024 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Lymphoma Lymphoma, B-Cell Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Mantle-Cell Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders |
Immune System Diseases Lymphoma, Non-Hodgkin Leukemia, Lymphoid Leukemia Hematologic Diseases Leukemia, B-Cell Chronic Disease Disease Attributes Pathologic Processes |